Need help finding what you are looking for?
Contact Us
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1794502
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1794502
Multiple Myeloma Drugs
PUBLISHED:
PAGES: 274 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Global Multiple Myeloma Drugs Market to Reach US$28.6 Billion by 2030
The global market for Multiple Myeloma Drugs estimated at US$21.2 Billion in the year 2024, is expected to reach US$28.6 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$11.0 Billion by the end of the analysis period. Growth in the Biologic Therapy segment is estimated at 6.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$5.8 Billion While China is Forecast to Grow at 8.0% CAGR
The Multiple Myeloma Drugs market in the U.S. is estimated at US$5.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.6 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.
Global Multiple Myeloma Drugs Market - Key Trends & Drivers Summarized
Why Is Drug Development for Multiple Myeloma Advancing Rapidly?
Multiple myeloma remains one of the most actively researched hematologic cancers due to its complex pathology and recurring nature. While it remains incurable in most cases, advances in drug development have led to significant improvements in disease management and patient survival. Therapeutic approaches now combine immunomodulators, proteasome inhibitors, monoclonal antibodies, and corticosteroids. These combinations form the backbone of induction, maintenance, and relapsed therapy regimens. New drug classes and targeted therapies are expanding the treatment landscape for both newly diagnosed and refractory patients.
Treatment goals include deepening remission, delaying relapse, and managing side effects with improved precision. Personalized regimens are becoming common, based on genetic markers, cytogenetic risk, and prior response. The growing use of triplet and quadruplet regimens, as well as stem cell transplantation in eligible patients, reflects an evolving clinical strategy that seeks durable responses while minimizing toxicity. As multiple myeloma is highly heterogeneous, therapeutic choices increasingly reflect patient-specific disease characteristics and tolerance profiles.
What Innovations Are Shaping the Next Generation of Multiple Myeloma Therapies?
Recent innovations include the introduction of monoclonal antibodies targeting surface antigens such as CD38 and SLAMF7, which enhance immune-mediated killing of myeloma cells. These agents, often combined with established therapies, have shown meaningful improvements in progression-free survival. Bispecific T-cell engagers (BiTEs) and antibody-drug conjugates (ADCs) are also being studied for their ability to directly engage tumor cells while harnessing immune response.
Cell-based therapies such as CAR T-cell treatments have become a major area of interest for heavily pretreated or relapsed patients. These therapies involve engineering a patient’s own T-cells to target myeloma-specific antigens. Though currently reserved for advanced cases, ongoing trials are assessing their potential earlier in the treatment sequence. Oral proteasome inhibitors and second-generation immunomodulators are being developed to improve convenience and reduce adverse effects, especially in long-term maintenance settings.
Which Patient Segments and Healthcare Settings Are Driving Demand?
Relapsed and refractory patients represent the fastest-growing treatment segment, requiring novel agents with new mechanisms of action. Elderly patients and those with comorbidities often require lower-intensity regimens, creating demand for oral or subcutaneous formulations that can be administered outside of hospital settings. Outpatient infusion centers, specialty pharmacies, and home healthcare providers are increasingly involved in care delivery, especially as treatment durations extend over months or years.
Diagnostic improvements are enabling earlier identification and risk stratification, leading to earlier intervention in high-risk patients. Supportive care for managing bone disease, renal dysfunction, and treatment-related side effects is also improving, allowing broader access to combination regimens. Payers and providers are emphasizing value-based care, focusing on therapies that demonstrate long-term disease control with acceptable toxicity profiles. This shift is influencing formulary inclusion and patient access strategies worldwide.
Growth in the Multiple Myeloma Drugs Market Is Driven by Several Factors…
Growth in the multiple myeloma drugs market is driven by several factors. Rising global incidence, particularly in aging populations, is expanding the treatment pool. Continuous innovation in immunotherapies, cell therapies, and targeted agents supports clinical adoption and label expansion. Improved diagnostic precision allows for risk-adapted treatment planning, increasing demand for both frontline and salvage therapies. Shift toward outpatient and home-based treatment delivery boosts use of oral and subcutaneous agents. Growing acceptance of combination regimens and maintenance therapy extends duration of treatment, generating sustained demand. Investment by biopharmaceutical companies in pipeline development and clinical trials further accelerates market expansion across regions.
SCOPE OF STUDY:
The report analyzes the Multiple Myeloma Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Therapy (Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 34 Featured) -
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca plc
- Bayer AG
- Biogen Idec
- bluebird bio, Inc.
- Bristol-Myers Squibb (Celgene)
- Cipla Inc.
- Daiichi Sankyo
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson (Janssen)
- Karyopharm Therapeutics Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Seagen (Pfizer subsidiary)
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Product Code: MCP37461
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Multiple Myeloma Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Global Prevalence of Multiple Myeloma Spurs Continuous Development of Novel Therapeutic Agents
- Advancements in Monoclonal Antibodies and CAR-T Cell Therapies Drive Innovation in Treatment Options
- FDA Approvals of First-in-Class Drugs Strengthen Competitive Landscape and Accelerate Pipeline Growth
- Increased Focus on Personalized Medicine Throws Spotlight on Genotype-Specific Therapeutics
- Growing Use of Combination Therapies Enhances Treatment Efficacy and Sustains Demand for Multi-Drug Regimens
- Patient Preference for Oral and Targeted Therapies Spurs Development of Convenient Drug Delivery Formats
- Clinical Trial Expansion and Cross-Border Collaborations Accelerate Access to Experimental Therapies
- Rising Awareness and Early Diagnosis Improve Patient Eligibility for Advanced Drug Protocols
- Payer Support for High-Cost Therapies in Oncology Encourages Continued Investment in Premium Drugs
- Academic and Pharma Partnerships Fuel Discovery of Next-Generation Immunotherapies and Inhibitors
- Post-Transplant Maintenance Strategies Strengthen Market for Chronic and Long-Term Drug Use
- Improved Survival Rates Extend Treatment Cycles, Increasing Cumulative Drug Consumption
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Multiple Myeloma Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Multiple Myeloma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 4: World 16-Year Perspective for Multiple Myeloma Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Biologic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Biologic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 10: World 16-Year Perspective for Biologic Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 16: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 19: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 26: USA Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: USA Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 28: USA 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 29: USA Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: USA Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 31: USA 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- CANADA
- TABLE 32: Canada Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: Canada Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 34: Canada 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 35: Canada Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Canada Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 37: Canada 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- JAPAN
- Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 38: Japan Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Japan Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 40: Japan 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 41: Japan Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Japan Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 43: Japan 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- CHINA
- Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 44: China Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: China Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 46: China 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 47: China Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: China Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 49: China 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- EUROPE
- Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 50: Europe Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 51: Europe Historic Review for Multiple Myeloma Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 52: Europe 16-Year Perspective for Multiple Myeloma Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
- TABLE 53: Europe Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Europe Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 55: Europe 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 56: Europe Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Europe Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 58: Europe 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- FRANCE
- Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 59: France Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: France Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 61: France 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 62: France Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: France Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 64: France 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- GERMANY
- Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 65: Germany Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Germany Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 67: Germany 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 68: Germany Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Germany Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 70: Germany 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- ITALY
- TABLE 71: Italy Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Italy Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 73: Italy 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 74: Italy Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Italy Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 76: Italy 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- UNITED KINGDOM
- Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 77: UK Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: UK Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 79: UK 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 80: UK Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: UK Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 82: UK 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- SPAIN
- TABLE 83: Spain Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Spain Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 85: Spain 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 86: Spain Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Spain Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 88: Spain 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- RUSSIA
- TABLE 89: Russia Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Russia Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 91: Russia 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 92: Russia Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Russia Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 94: Russia 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- REST OF EUROPE
- TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Rest of Europe Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 97: Rest of Europe 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Rest of Europe Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 100: Rest of Europe 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- ASIA-PACIFIC
- Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 102: Asia-Pacific Historic Review for Multiple Myeloma Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 103: Asia-Pacific 16-Year Perspective for Multiple Myeloma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
- TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Asia-Pacific Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 106: Asia-Pacific 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Asia-Pacific Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 109: Asia-Pacific 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- AUSTRALIA
- Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 110: Australia Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Australia Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 112: Australia 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 113: Australia Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: Australia Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 115: Australia 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- INDIA
- Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 116: India Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: India Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 118: India 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 119: India Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: India Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 121: India 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- SOUTH KOREA
- TABLE 122: South Korea Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: South Korea Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 124: South Korea 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 125: South Korea Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: South Korea Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 127: South Korea 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 129: Rest of Asia-Pacific Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Rest of Asia-Pacific Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- LATIN AMERICA
- Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 134: Latin America Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 135: Latin America Historic Review for Multiple Myeloma Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 136: Latin America 16-Year Perspective for Multiple Myeloma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
- TABLE 137: Latin America Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 138: Latin America Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 139: Latin America 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 140: Latin America Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Latin America Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 142: Latin America 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- ARGENTINA
- TABLE 143: Argentina Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 144: Argentina Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 145: Argentina 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 146: Argentina Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 147: Argentina Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 148: Argentina 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- BRAZIL
- TABLE 149: Brazil Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 150: Brazil Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 151: Brazil 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 152: Brazil Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 153: Brazil Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 154: Brazil 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- MEXICO
- TABLE 155: Mexico Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 156: Mexico Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 157: Mexico 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 158: Mexico Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 159: Mexico Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 160: Mexico 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 162: Rest of Latin America Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 163: Rest of Latin America 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 165: Rest of Latin America Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 166: Rest of Latin America 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- MIDDLE EAST
- Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 167: Middle East Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 168: Middle East Historic Review for Multiple Myeloma Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 169: Middle East 16-Year Perspective for Multiple Myeloma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
- TABLE 170: Middle East Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 171: Middle East Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 172: Middle East 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 173: Middle East Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 174: Middle East Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 175: Middle East 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- IRAN
- TABLE 176: Iran Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 177: Iran Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 178: Iran 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 179: Iran Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 180: Iran Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 181: Iran 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- ISRAEL
- TABLE 182: Israel Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 183: Israel Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 184: Israel 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 185: Israel Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 186: Israel Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 187: Israel 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- SAUDI ARABIA
- TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 189: Saudi Arabia Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 190: Saudi Arabia 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 192: Saudi Arabia Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 193: Saudi Arabia 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 194: UAE Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 195: UAE Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 196: UAE 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 197: UAE Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 198: UAE Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 199: UAE 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 201: Rest of Middle East Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 202: Rest of Middle East 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 204: Rest of Middle East Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 205: Rest of Middle East 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
- AFRICA
- Multiple Myeloma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 206: Africa Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 207: Africa Historic Review for Multiple Myeloma Drugs by Therapy - Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 208: Africa 16-Year Perspective for Multiple Myeloma Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Biologic Therapy, Chemotherapy and Other Therapies for the Years 2014, 2025 & 2030
- TABLE 209: Africa Recent Past, Current & Future Analysis for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 210: Africa Historic Review for Multiple Myeloma Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 211: Africa 16-Year Perspective for Multiple Myeloma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
IV. COMPETITION
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.